Net earnings (USD, thousands)

Depreciation and amortization (USD, thousands)

Costs recognized on sale of acquired inventory (USD, thousands)

Stock-based compensation expense (USD, thousands)

(Gain) Loss on equity method investment (USD, thousands)

Asset impairment restructuring (USD, thousands)

Impairment of assets held-for-sale (USD, thousands)

Other operating activity (USD, thousands)

Net cash provided by (used in) operating activities (USD, thousands)

Proceeds from sale of available-for-sale investments (USD, thousands)

Purchases of available-for-sale investments (USD, thousands)

Additions to property and equipment (USD, thousands)

Acquisitions, net of cash acquired (USD, thousands)

Distributions from (Investments in) Wilson Wolf (USD, thousands)

Proceeds from sale of assets held-for-sale (USD, thousands)

Net cash provided by (used in) investing activities (USD, thousands)

Cash dividends (USD, thousands)

Proceeds from stock option exercises (USD, thousands)

Re-purchases of common stock (USD, thousands)

Borrowings under line-of-credit agreement (USD, thousands)

Repayments of long-term debt (USD, thousands)

Taxes paid on RSUs and net share settlements (USD, thousands)

Net cash provided by (used in) financing activities (USD, thousands)

Effect of exchange rate changes on cash and cash equivalents (USD, thousands)

Net change in cash and cash equivalents (USD, thousands)

Cash paid for income taxes (USD, thousands)

Cash paid for interest (USD, thousands)

Deferred income taxes (USD, thousands)

Fair value adjustment to contingent consideration payable (USD, thousands)

Fair value adjustment on available-for-sale investments (USD, thousands)

Leases, net (USD, thousands)

Investment in Spear Bio (USD, thousands)

Cash and cash equivalents at beginning of period (USD, thousands)

Cash and cash equivalents at end of period (USD, thousands)

ac8833fe03ffd4786b7d8a20041906686d6cd78a3d2bb8be6a34917463f23eec

Net sales (USD, thousands)

Cost of sales (USD, thousands)

Gross margin (USD, thousands)

Selling, general and administrative expenses (USD, thousands)

Research and development expenses (USD, thousands)

Total operating expenses (USD, thousands)

Operating income (USD, thousands)

Other income (expense) (USD, thousands)

Earnings before income taxes (USD, thousands)

Income taxes (USD, thousands)

Basic earnings per share (USD)

Diluted earnings per share (USD)

Basic weighted average common shares outstanding (thousands)

Diluted weighted average common shares outstanding (thousands)

c936effcb5e24365bb9ae8811e3d715c57a2940bf690588c87bd960c384bbda7

Cash and cash equivalents (USD, thousands)

Short-term available-for-sale investments (USD, thousands)

Accounts receivable, net (USD, thousands)

Inventories (USD, thousands)

Current assets held-for-sale (USD, thousands)

Other current assets (USD, thousands)

Total current assets (USD, thousands)

Property and equipment, net (USD, thousands)

Right-of-use assets (USD, thousands)

Other assets (USD, thousands)

Total assets (USD, thousands)

Contract liabilities (USD, thousands)

Income taxes payable (USD, thousands)

Operating lease liabilities - current (USD, thousands)

Other current liabilities (USD, thousands)

Total current liabilities (USD, thousands)

Long-term debt obligations (USD, thousands)

Operating lease liabilities (USD, thousands)

Other long-term liabilities (USD, thousands)

Total Bio-Techne’s shareholders’ equity (USD, thousands)

Total liabilities and shareholders’ equity (USD, thousands)

dddcb88ea75fea38e4e4e6fcbf349fe3b6489f2f3f0f55ad3fea34b063bb876a

4f04578074720372c6ecd10067de3b13e3cba3d9f4b7bc0076d01a4f509aa897

10abba1dc60b6aff5fc172fbf70c4cdf05facde15257aa8c4a9c8491270fb5ab

Adjustments for Non-Cash Items [USD, Thousands]

Stock-Based Compensation [USD, Thousands]

Changes in Working Capital [USD, Thousands]

Capital Expenditures (CapEx) [USD, Thousands]

Proceeds from Debt [USD, Thousands]

Repayments of Debt [USD, Thousands]

Share Repurchases [USD, Thousands]

Dividend Payments [USD, Thousands]

Net Change in Cash [USD, Thousands]

f6d2971b69cfe51adf01e5740b618a65ca6b68674cfa57d224bc832df7ef95a0

Organic growth for Protein Sciences (percentage)

Sales reduction from exclusion of held-for-sale business (percentage)

Organic revenue growth for Diagnostics and Spatial Biology (percentage)

5333cd5ca24b1a3ea7abae89472e225e4abadbee01c2149c9ec7b4e21ff323e6

b3ca88231770ed802058871c2435b78bbb03109cf3a974db9c4df3eb2ec03687

United States

EMEA

United Kingdom

- United Kingdom

- EMEA, excluding United Kingdom

APAC

- APAC, excluding Greater China

Greater China

Rest of World

Other Asia

Total Revenue

4bdd9104f4917b6e3e99ed12df6d2d6a7dd8577d15d58f28bf01b56b731fcc1c

BIO-TECHNE (TECH)

Financials